221 related articles for article (PubMed ID: 24269918)
1. Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine.
Jain MK; Bhat R
Neurobiol Dis; 2014 Mar; 63():115-28. PubMed ID: 24269918
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
4. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
5. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
6. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.
Follmer C; Romão L; Einsiedler CM; Porto TC; Lara FA; Moncores M; Weissmüller G; Lashuel HA; Lansbury P; Neto VM; Silva JL; Foguel D
Biochemistry; 2007 Jan; 46(2):472-82. PubMed ID: 17209557
[TBL] [Abstract][Full Text] [Related]
7. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
Singh P; Bhat R
ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
[TBL] [Abstract][Full Text] [Related]
8. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
10. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
Park SS; Lee D
Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
[TBL] [Abstract][Full Text] [Related]
11. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.
Braga CA; Follmer C; Palhano FL; Khattar E; Freitas MS; Romão L; Di Giovanni S; Lashuel HA; Silva JL; Foguel D
J Mol Biol; 2011 Jan; 405(1):254-73. PubMed ID: 21050861
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells.
Khalife M; Morshedi D; Aliakbari F; Tayaranian Marvian A; Mohammad Beigi H; Azimzadeh Jamalkandi S; Pan-Montojo F
Protein J; 2015 Aug; 34(4):291-303. PubMed ID: 26250981
[TBL] [Abstract][Full Text] [Related]
13. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
[TBL] [Abstract][Full Text] [Related]
14. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
15. Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation.
Xu B; Fan F; Liu Y; Liu Y; Zhou L; Yu H
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238596
[TBL] [Abstract][Full Text] [Related]
16. Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay.
Martin FL; Williamson SJ; Paleologou KE; Hewitt R; El-Agnaf OM; Allsop D
J Neurochem; 2003 Nov; 87(3):620-30. PubMed ID: 14535945
[TBL] [Abstract][Full Text] [Related]
17. Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation.
Goodwin J; Nath S; Engelborghs Y; Pountney DL
Neurochem Int; 2013 Apr; 62(5):703-11. PubMed ID: 23159813
[TBL] [Abstract][Full Text] [Related]
18. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of alpha-synuclein aggregation by homologous peptides.
Du HN; Li HT; Zhang F; Lin XJ; Shi JH; Shi YH; Ji LN; Hu J; Lin DH; Hu HY
FEBS Lett; 2006 Jun; 580(15):3657-64. PubMed ID: 16764865
[TBL] [Abstract][Full Text] [Related]
20. Effects of exogenous alpha-synuclein on stimulated dopamine overflow in dorsal striatum.
Pelkonen A; Kallunki P; Yavich L
Neurosci Lett; 2013 Oct; 554():141-5. PubMed ID: 24021803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
